Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Optofluidic Platform to Aide in Immunotherapy Development

publication date: Jul 29, 2019
 | 
author/source: Berkeley Lights, Inc. (BLI)

Optofluidic-Platform-to-Aide-in-Immunotherapy-Development


Berkeley Lights, Inc. (BLI), the leader in digital cell biology, has announced the launch of the Lightning™ optofluidic platform, which directly visualizes phenotype and function of 1000s of T cells in days to help scientists address challenges in developing cancer immunotherapies.

The product was showcased at the upcoming 34th Congress of the International Society for Advancement of Cytometry (CYTO) in Vancouver, Canada from June 22 to 26.

Over the last decade, scientists have advanced their understanding of immune cell function in many contexts, including cancer. Progress, however, has been slow because identification of immune cell functional signatures requires time consuming processes that average individual cell behaviors and interactions.

“Analysis of T cell function has largely been based on assessing the activity of an entire population of cells, which reduces the resolution of our results,” said Alan Ashworth, PhD, FRS, president of the Helen Diller Family Comprehensive Cancer Center. “Deeper insights are needed to let us see differences that enable us to draw more informed conclusions about T cell function. This will improve our understanding of cancer immunotherapeutics.”

The Lightning platform allows scientists to easily visualize phenotype and perform functional analysis on 100s to 1000s of individual cells simultaneously on a single platform in just a few days. Using Berkeley Lights’ proprietary optofluidic technology, individual T cells can be loaded into NanoPenTM chambers with other cell types to assess cell-cell interactions, cell surface phenotype, cytotoxicity, and cytokine secretion, yielding a more detailed picture of individual cell function within a population. The entire process is digitally recorded for visual confirmation of results and on-instrument data analysis. The platform is also designed to overcome one of the major hurdles to most existing cellular assays – destruction of the cell during analysis – by enabling scientists to recover live cells after completion of functional assays.

“With the new Lightning platform, scientists across the research and development pipeline, from academia to top pharmaceutical companies, can more precisely and quickly design, build, and test new assays to uncover the function of T cells, speeding their efforts to improve cancer immunotherapies,” said Eric Hobbs, CEO at Berkeley Lights, Inc. “Lightning is an agile desktop platform built for scientists who push the boundaries of individual cell analysis and we believe this is a key step in our goal of democratizing digital cell biology.”

 

more about berkeley lights




 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events